Fibrosis Related Inflammatory Mediators: Role of the IL-10 Cytokine Family

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Sziksz, Erna ^a,b   Pap, Domonkos ^b   Lippai, Rita ^b   Béres, Nóra Judit ^b   Fekete, Andrea ^a   Szabó, Attila J ^a   Vannay, Ádám ^a,b  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 19; INTERLEUKIN 20; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 24; INTERLEUKIN 26; INTERLEUKIN 28; INTERLEUKIN 28A; INTERLEUKIN 28B; INTERLEUKIN 29; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MACROPHAGE ELASTASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PLATELET DERIVED GROWTH FACTOR; SOMATOMEDIN; STAT3 PROTEIN; STAT6 PROTEIN; STROMELYSIN; TRANSFORMING GROWTH FACTOR BETA; CYTOKINE; IL10 PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; BASOPHIL; CD8+ T LYMPHOCYTE; CHRONIC INFLAMMATION; CYTOKINE RELEASE; EOSINOPHIL; FIBROSIS; HEART MUSCLE FIBROSIS; HOST RESISTANCE; HUMAN; INTESTINAL FIBROSIS; KIDNEY FIBROSIS; LUNG FIBROSIS; LYMPHOCYTE; MACROPHAGE; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RENAL REPLACEMENT THERAPY; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL; BLOOD; IMMUNOLOGY; INFLAMMATION; METABOLISM;

CYTOKINES; FIBROSIS; HUMANS; INFLAMMATION; INTERLEUKIN-10;

EID: 84936806414     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/764641     Document Type: Review

References (163)

1. T. A. Wynn, "Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases, " The Journal of Clinical Investigation, vol. 117, no. 3, pp. 524-529, 2007.
2. M. Pinzani, "Welcome to Fibrogenesis & Tissue Repair, " Fibrogenesis & Tissue Repair, vol. 1, no. 1, article 1, 2 pages, 2008.
3. T. R. Cox and J. T. Erler, "Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer, " Disease Models and Mechanisms, vol. 4, no. 2, pp. 165-178, 2011.
4. T. A. Wynn, "Cellular and molecular mechanisms of fibrosis, " The Journal of Pathology, vol. 214, no. 2, pp. 199-210, 2008.
5. J. J. Tomasek, G. Gabbiani, B. Hinz, C. Chaponnier, and R. A. Brown, "Myofibroblasts and mechano-regulation of connective tissue remodelling, " Nature Reviews Molecular Cell Biology, vol. 3, no. 5, pp. 349-363, 2002.
6. G. Latella, J. Di Gregorio, V. Flati, F. Rieder, and I.C. Lawrance, "Mechanisms of initiation and progression of intestinal fibrosis in IBD, " Scandinavian Journal of Gastroenterology, vol. 50, no. 1, pp. 53-65, 2015.
7. P. Blair and R. Flaumenhaft, "Platelet -granules: basic biology and clinical correlates, " Blood Reviews, vol. 23, no. 4, pp. 177-189, 2009.
8. J. A. Coppinger, G. Cagney, S. Toomey et al., "Characterization of the proteins released fromactivated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions, " Blood, vol. 103, no. 6, pp. 2096-2104, 2004.
9. M. R. De Pascale, L. Sommese, A. Casamassimi, and C. Napoli, "Platelet derivatives in regenerative medicine: an update, " Transfusion Medicine Reviews, vol. 29, no. 1, pp. 52-61, 2015.
10. B. Eyden, "The myofibroblast: phenotypic characterization as a prerequisite to understanding its functions in translational medicine, " Journal of Cellular and Molecular Medicine, vol. 12, no. 1, pp. 22-37, 2008.
11. O. DeWever, P. Demetter, M. Mareel, and M. Bracke, "Stromal myofibroblasts are drivers of invasive cancer growth, " International Journal of Cancer, vol. 123, no. 10, pp. 2229-2238, 2008.
12. F. Strutz and M. Zeisberg, "Renal fibroblasts andmyofibroblasts in chronic kidney disease, " Journal of the American Society of Nephrology, vol. 17, no. 11, pp. 2992-2998, 2006.
13. S.-L. Lin, T. Kisseleva, D. A. Brenner, and J. S. Duffield, "Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney, " The American Journal of Pathology, vol. 173, no. 6, pp. 1617-1627, 2008.
14. R. G. Wells, "The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis, " Journal of Clinical Gastroenterology, vol. 39, supplement 2, no. 4, pp. S158-S161, 2005.
15. A. Forte, A. Della Corte, M. De Feo, F. Cerasuolo, and M. Cipollaro, "Role of myofibroblasts in vascular remodelling: focus on restenosis and aneurysm, " Cardiovascular Research, vol. 88, no. 3, pp. 395-405, 2010.
16. K. Aoyagi-Ikeda, T. Maeno, H. Matsui et al., "Notch induces myofibroblast differentiation of alveolar epithelial cells via transforming growth factor-β -Smad3 pathway, " The American Journal of Respiratory Cell and Molecular Biology, vol. 45, no. 1, pp. 136-144, 2011.
17. U. Sen, K. S. Moshal, N. Tyagi, G. K. Kartha, and S. C. Tyagi, "Homocysteine-induced myofibroblast differentiation in mouse aortic endothelial cells, " Journal of Cellular Physiology, vol. 209, no. 3, pp. 767-774, 2006.
18. E. Sziksz, A. Veres-Szekely, D. Pap et al., "Mucosal architectural rearrangement in coeliac disease, " International Journal of Celiac Disease, vol. 2, no. 3, pp. 89-92, 2014.
19. M. Schmidt, G. Sun, M. A. Stacey, L. Mori, and S. Mattoli, "Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma, " The Journal of Immunology, vol. 171, no. 1, pp. 380-389, 2003.
20. K. A. Cieslik, J. Trial, and M. L. Entman, "Defective myofibroblast formation from mesenchymal stem cells in the aging murine heart: rescue by activation of the AMPK pathway, " The American Journal of Pathology, vol. 179, no. 4, pp. 1792-1806, 2011.
21. P. Bainbridge, "Wound healing and the role of fibroblasts, " Journal ofWound Care, vol. 22, no. 8, pp. 407-412, 2013.
22. N. J. Kenyon, R. W. Ward, G. McGrew, and J. A. Last, "TGF-β 1 causes airway fibrosis and increased collagen I and III mRNA in mice, " Thorax, vol. 58, no. 9, pp. 772-777, 2003.
23. B. Wang, R. Komers, R. Carew et al., "Suppression of microRNA-29 expression by TGF-β 1 promotes collagen expression and renal fibrosis, " Journal of theAmerican Society of Nephrology, vol. 23, no. 2, pp. 252-265, 2012.
24. S. Fichtner-Feigl, C. A. Young, A. Kitani, E. K. Geissler, H.-J. Schlitt, and W. Strober, "IL-13 signaling via IL-13R alpha2 induces major downstreamfibrogenic factorsmediating fibrosis in chronic TNBS colitis, " Gastroenterology, vol. 135, no. 6, pp. 2003.e7-2013.e7, 2008.
25. A. Leask, "Getting to the heart of the matter: new insights into cardiac fibrosis, " Circulation Research, vol. 116, no. 7, pp. 1269-1276, 2015.
26. A. M. Gressner and R. Weiskirchen, "Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets, " Journal of Cellular and Molecular Medicine, vol. 10, no. 1, pp. 76-99, 2006.
27. I. C. Lawrance, G. Rogler, G. Bamias et al., "Cellular and molecular mediators of intestinal fibrosis, " Journal of Crohns and Colitis, 2014.
28. I. E. Dumitriu, D. R. Dunbar, S. E. Howie, T. Sethi, and C. D. Gregory, "Human dendritic cells produce TGF-β 1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells, " The Journal of Immunology, vol. 182, no. 5, pp. 2795-2807, 2009.
29. M. C. Kullberg, V. Hay, A. W. Cheever et al., "TGF-beta1 production by CD4+CD25+ regulatory T cells is not essential for suppression of intestinal inflammation, " European Journal of Immunology, vol. 35, no. 10, pp. 2886-2895, 2005.
30. J. H. Kehrl, L. M. Wakefield, A. B. Roberts et al., "Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth, " Journal of Experimental Medicine, vol. 163, no. 5, pp. 1037-1050, 1986.
31. J. M. Lopez-Guisa, C. Powers, D. File, E. Cochrane, N. Jimenez, and J. S. Debley, "Airway epithelial cells fromasthmatic children differentially express proremodeling factors, " Journal of Allergy and Clinical Immunology, vol. 129, no. 4, pp. 990.e6-997.e6, 2012.
32. R. Derynck and Y. E. Zhang, "Smad-dependent and Smadindependent pathways in TGF-β family signalling, " Nature, vol. 425, no. 6958, pp. 577-584, 2003.
33. S. Liu, X. Shi-Wen, L. Kennedy et al., "FAKis required forTGFβ -induced JNK phosphorylation in fibroblasts: implications for acquisition of amatrix-remodeling phenotype, "Molecular Biology of the Cell, vol. 18, no. 6, pp. 2169-2178, 2007.
34. A. Leask, "Targeting the TGFβ , endothelin-1 and CCN2 axis to combat fibrosis in scleroderma, " Cellular Signalling, vol. 20, no. 8, pp. 1409-1414, 2008.
35. A. T. Grazul-Bilska, M. L. Johnson, J. J. Bilski et al., "Wound healing: the role of growth factors, " Drugs of Today, vol. 39, no. 10, pp. 787-800, 2003.
36. J. C. Bonner, "Regulation of PDGF and its receptors in fibrotic diseases, " Cytokine and Growth Factor Reviews, vol. 15, no. 4, pp. 255-273, 2004.
37. A. Leask, A. Holmes, and D. J. Abraham, "Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis, " Current Rheumatology Reports, vol. 4, no. 2, pp. 136-142, 2002.
38. P.M. Krein, P. J. B. Sabatini, W. Tinmouth, F. H. Y. Green, and B. W. Winston, "Localization of insulin-like growth factor-I in lung tissues of patients with fibroproliferative acute respiratory distress syndrome, "AmericanJournal of Respiratory andCritical Care Medicine, vol. 167, no. 1, pp. 83-90, 2003.
39. M. Hetzel, M. Bachem, D. Anders, G. Trischler, and M. Faehling, "Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts, " Lung, vol. 183, no. 4, pp. 225-237, 2005.
40. S. Gupta, M.R. Clarkson, J. Duggan, and H. R. Brady, "Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis, " Kidney International, vol. 58, no. 4, pp. 1389-1399, 2000.
41. W.-H. Hahn, J.-S. Suh, and B.-S. Cho, "Polymorphisms of insulin-like growth factor-1 (IGF-1) and IGF-1 receptor (IGF-1R) contribute to pathologic progression in childhood IgA nephropathy, " Growth Factors, vol. 29, no. 1, pp. 8-13, 2011.
42. A. Di Sabatino, R. Ciccocioppo, E. Armellini et al., "Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohns disease, " Inflammatory Bowel Diseases, vol. 10, no. 5, pp. 573-577, 2004.
43. P. Hoffmann, M. Reinshagen, J. M. Zeeh et al., "Increased expression of epidermal growth factor-receptor in an experimental model of colitis in rats, " Scandinavian Journal of Gastroenterology, vol. 35, no. 11, pp. 1174-1180, 2000.
44. J. MacLean and K. B. Pasumarthi, "Signaling mechanisms regulating fibroblast activation, phenoconversion and fibrosis in the heart, " Indian Journal of Biochemistry & Biophysics, vol. 51, no. 6, pp. 476-482, 2014.
45. E. Falleti, S. Cmet, C. Fabris et al., "Association between the epidermal growth factor rs4444903 G/G genotype and advanced fibrosis at a young age in chronic hepatitis C, " Cytokine, vol. 57, no. 1, pp. 68-73, 2012.
46. M. Giannandrea and W. C. Parks, "Diverse functions of matrix metalloproteinases during fibrosis, " DMM Disease Models and Mechanisms, vol. 7, no. 2, pp. 193-203, 2014.
47. F. Huaux, J. Louahed, B. Hudspith et al., "Role of interleukin-10 in the lung response to silica in mice, " American Journal of Respiratory Cell and Molecular Biology, vol. 18, no. 1, pp. 51-59, 1998.
48. K. Nakagome, M. Dohi, K. Okunishi, R. Tanaka, J. Miyazaki, and K. Yamamoto, "In vivo IL-10 gene delivery attenuates bleomycin induced pulmonary fibrosis by inhibiting the production and activation ofTGF-β in the lung, " Thorax, vol. 61, no. 10, pp. 886-894, 2006.
49. E. H. Alhamad, J. G. Cal, Z. Shakoor, A. Almogren, and A. A. AlBoukai, "Cytokine gene polymorphisms and serum cytokine levels in patients with idiopathic pulmonary fibrosis, " BMC Medical Genetics, vol. 14, no. 1, article 66, 2013.
50. E. M. Minshall, A. Tsicopoulos, Z. Yasruel et al., "Cytokine mRNA gene expression in active and nonactive pulmonary sarcoidosis, " European Respiratory Journal, vol. 10, no. 9, pp. 2034-2039, 1997.
51. V. Barbarin, M. Petrek, V. Kolek, J. Van Snick, F. Huaux, and D. Lison, "Characterization of p40 and IL-10 in the BALF of patients with pulmonary sarcoidosis, " Journal of Interferon and Cytokine Research, vol. 23, no. 8, pp. 449-456, 2003.
52. W. Kucejko, E. Chyczewska, W. Naumnik, and M. Ossolińska, "Concentration of surfactant protein D, Clara cell protein CC-16 and IL-10 in bronchoalveolar lavage (BAL) in patients with sarcoidosis, hypersensivity pneumonitis and idiopathic pulmonary fibrosis, " FoliaHistochemica et Cytobiologica, vol. 47, no. 2, pp. 225-230, 2009.
53. Y. Jin, R. Liu, J. Xie, H. Xiong, J. C. He, and N. Chen, "Interleukin-10 deficiency aggravates kidney inflammation and fibrosis in the unilateral ureteral obstruction mouse model, " Laboratory Investigation, vol. 93, no. 7, pp. 801-811, 2013.
54. C. B. Rodell, R. Rai, S. Faubel, J. A. Burdick, and D. E. Soranno, "Local immunotherapy via delivery of interleukin-10 and transforming growth factor β antagonist for treatment of chronic kidney disease, " Journal of Controlled Release, vol. 206, pp. 131-139, 2015.
55. D. E. Soranno, H.D. Lu, H. M. Weber, R. Rai, and J.A. Burdick, "Immunotherapy with injectable hydrogels to treat obstructive nephropathy, " Journal of Biomedical Materials Research Part A, vol. 102, no. 7, pp. 2173-2180, 2014.
56. T. Kucharzik, R. Stoll, N. Lugering, and W. Domschke, "Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD), " Clinical and Experimental Immunology, vol. 100, no. 3, pp. 452-456, 1995.
57. C. Gasche, S. Bakos, C. Dejaco, W. Tillinger, S. Zakeri, and W. Reinisch, "IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel disease, " Journal of Clinical Immunology, vol. 20, no. 5, pp. 362-370, 2000.
58. O. H. Nielsen, T. Køppen, N. Rüdiger, T. Horn, J. Eriksen, and I. Kirman, "Involvement of interleukin-4 and -10 in inflammatory bowel disease, " Digestive Diseases and Sciences, vol. 41, no. 9, pp. 1786-1793, 1996.
59. D. Kotlarz, R. Beier, D. Murugan et al., "Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy, " Gastroenterology, vol. 143, no. 2, pp. 347-355, 2012.
60. G. J. Marlow, D. van Gent, and L. R. Ferguson, "Why interleukin-10 supplementation does not work in Crohns disease patients, " World Journal of Gastroenterology, vol. 19, no. 25, pp. 3931-3941, 2013.
61. M. C. Li and S. H. He, "IL-10 and its related cytokines for treatment of inflammatory bowel disease, " World Journal of Gastroenterology, vol. 10, no. 5, pp. 620-625, 2004.
62. S. K. Verma, P. Krishnamurthy, D. Barefield et al., "Interleukin-10 treatment attenuates pressure overload-induced hypertrophic remodeling and improves heart function via signal transducers and activators of transcription 3-dependent inhibition of nuclear factor-B, " Circulation, vol. 126, no. 4, pp. 418-429, 2012.
63. P. Krishnamurthy, J. Rajasingh, E. Lambers, G. Qin, D. W. Losordo, and R. Kishore, "IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR, " Circulation Research, vol. 104, no. 2, pp. e9-e18, 2009.
64. P. M. M. Guedes, V. M. Veloso, L. C. C. Afonso et al., "Development of chronic cardiomyopathy in canine Chagas disease correlates with high IFN-, TNF-, and low IL-10 production during the acute infection phase, " Veterinary Immunology and Immunopathology, vol. 130, no. 1-2, pp. 43-52, 2009.
65. O. Zimmermann, J. M. Homann, A. Bangert et al., "Successful use of mRNA-nucleofection for overexpression of interleukin-10 in murine monocytes/macrophages for anti-inflammatory therapy in amurinemodel of autoimmunemyocarditis, " Journal of the American Heart Association, vol. 1, no. 6, Article ID e003293, 2012.
66. L. Hammerich and F. Tacke, "Interleukins in chronic liver disease: lessons learned from experimental mouse models, " Clinical and Experimental Gastroenterology, vol. 7, pp. 297-306, 2014.
67. K. Thompson, J. Maltby, J. Fallowfield, M. McAulay, H. Millward-Sadler, and N. Sheron, "Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis, " Hepatology, vol. 28, no. 6, pp. 1597-1606, 1998.
68. H. Louis, J. L. van Laethem, W. Wu et al., "Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice, " Hepatology, vol. 28, no. 6, pp. 1607-1615, 1998.
69. K. S. Hung, T. H. Lee, W. Y. Chou et al., "Interleukin-10 gene therapy reverses thioacetamide-induced liver fibrosis in mice, " Biochemical and Biophysical Research Communications, vol. 336, no. 1, pp. 324-331, 2005.
70. P. Jennings, D. Crean, L. Aschauer et al., "Interleukin-19 as a translational indicator of renal injury, " Archives of Toxicology, vol. 89, no. 1, pp. 101-106, 2015.
71. Y.-H. Hsu, H.-H. Li, J.-M. Sung, W.-T. Chen, Y.-C. Hou, and M.-S. Chang, "Interleukin-19 mediates tissue damage inmurine ischemic acute kidney injury, " PLoS ONE, vol. 8, no. 2, Article ID e56028, 2013.
72. J. K. Yamamoto-Furusho, E. Alvarez-León, J. M. Fragoso, A. Gozalishvilli, M. Vallejo, and G. Vargas-Alarcón, "Protective role of interleukin-19 gene polymorphisms in patients with ulcerative colitis, " Human Immunology, vol. 72, no. 11, pp. 1029-1032, 2011.
73. Y.-T. Azuma, Y. Matsuo, M. Kuwamura et al., "Interleukin-19 protects mice from innate-mediated colonic inflammation, " Inflammatory Bowel Diseases, vol. 16, no. 6, pp. 1017-1028, 2010.
74. C.-C. Wei, H.-H. Li, Y.-H. Hsu, C.-H. Hsing, J.-M. Sung, and M.-S. Chang, "Interleukin-20 targets renal cells and is associated with chronic kidney disease, " Biochemical and Biophysical Research Communications, vol. 374, no. 3, pp. 448-453, 2008.
75. H.-H. Li, Y.-H. Hsu, C.-C. Wei, P.-T. Lee, W.-C. Chen, and M.-S. Chang, "Interleukin-20 induced cell death in renal epithelial cells and was associated with acute renal failure, " Genes and Immunity, vol. 9, no. 5, pp. 395-404, 2008.
76. G. Fonseca-Camarillo, J. Furuzawa-Carballeda, L. Llorente, and J. K. Yamamoto-Furusho, "IL-10-and IL-20-expressing epithelial and inflammatory cells are increased in patients with ulcerative colitis, " Journal of Clinical Immunology, vol. 33, no. 3, pp. 640-648, 2013.
77. Y. S. Chiu, C. Wei, Y. Lin, Y. Hsu, and M. Chang, "IL-20 and IL-20R1 antibodies protect against liver fibrosis, " Hepatology, vol. 60, no. 3, pp. 1003-1014, 2014.
78. M. Liang, J. Wang, H. Chu et al., "Interleukin-22 inhibits bleomycin-induced pulmonary fibrosis, " Mediators of Inflammation, vol. 2013, Article ID 209179, 11 pages, 2013.
79. P. L. Simonian, F. Wehrmann, C. L. Roark, W. K. Born, R. L. OBrien, and A. P. Fontenot, "T cells protect against lung fibrosis via IL-22, " Journal of Experimental Medicine, vol. 207, no. 10, pp. 2239-2253, 2010.
80. M. J. Xu, D. Feng, H. Wang, Y. Guan, X. Yan, and B. Gao, "IL-22 ameliorates renal ischemia-reperfusion injury by targeting proximal tubule epithelium, " Journal of the American Society of Nephrology, vol. 25, no. 5, pp. 967-977, 2014.
81. S. Brand, F. Beigel, T. Olszak et al., "IL-22 is increased in active Crohns disease andpromotes proinflammatorygene expression and intestinal epithelial cellmigration, "TheAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 290, no. 4, pp. G827-G838, 2006.
82. G. Pickert, C. Neufert, M. Leppkes et al., "STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing, " The Journal of Experimental Medicine, vol. 206, no. 7, pp. 1465-1472, 2009.
83. L. A. Zenewicz, G. D. Yancopoulos, D. M. Valenzuela, A. J. Murphy, S. Stevens, and R. A. Flavell, "Innate and adaptive interleukin-22 protects mice frominflammatory bowel disease, " Immunity, vol. 29, no. 6, pp. 947-957, 2008.
84. Y. Guo, W. Wu, Z. Cen, X. Li, Q. Kong, and Q. Zhou, "IL-22-producing Th22 cells play a protective role in CVB3-induced chronic myocarditis and dilated cardiomyopathy by inhibiting myocardial fibrosis, " Virology Journal, vol. 11, article 230, 2014.
85. X. Kong, D. Feng, S. Mathews, and B. Gao, "Hepatoprotective and anti-fibrotic functions of interleukin-22: therapeutic potential for the treatment of alcoholic liver disease, " Journal of Gastroenterology and Hepatology, vol. 28, supplement 1, pp. 56-60, 2013.
86. S. H. Ki, O. Park, M. Zheng et al., "Interleukin-22 treatment ameliorates alcoholic liver injury in amurine model of chronicbinge ethanol feeding: role of signal transducer and activator of transcription 3, " Hepatology, vol. 52, no. 4, pp. 1291-1300, 2010.
87. L. Yang, Y. Zhang, L. Wang et al., "Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22, " Journal of Hepatology, vol. 53, no. 2, pp. 339-347, 2010.
88. X. Kong, D. Feng, H. Wang et al., "Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice, " Hepatology, vol. 56, no. 3, pp. 1150-1159, 2012.
89. S. Radaeva, R. Sun, H.-N. Pan, F. Hong, and B. Gao, "Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation, " Hepatology, vol. 39, no. 5, pp. 1332-1342, 2004.
90. L. Y. Wu, S. Liu, Y. Liu et al., "Up-regulation of interleukin-22 mediates liver fibrosis via activating hepatic stellate cells in patients with hepatitis C, " Clinical Immunology, vol. 158, no. 1, pp. 77-87, 2015.
91. G. Fonseca-Camarillo, J. Furuzawa-Carballeda, J. Granados, and J. K. Yamamoto-Furusho, "Expression of interleukin (IL)-19 and IL-24 in inflammatory bowel disease patients: a crosssectional study, " Clinical & Experimental Immunology, vol. 177, no. 1, pp. 64-75, 2014.
92. A. Andoh, M. Shioya, A. Nishida et al., "Expression of IL-24, an activator of the JAK1/STAT3/SOCS3 cascade, is enhanced in inflammatory bowel disease, " Journal of Immunology, vol. 183, no. 1, pp. 687-695, 2009.
93. E. Troncone, I. Marafini, F. Pallone, and G. Monteleone, "Th17 cytokines in inflammatory bowel diseases: discerning the good fromthe bad, " International Reviews of Immunology, vol. 32, no. 5-6, pp. 526-533, 2013.
94. Z. Zhu, R. J. Homer, Z. Wang et al., "Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production, " Journal of Clinical Investigation, vol. 103, no. 6, pp. 779-788, 1999.
95. J. A. Belperio, M. Dy, M. D. Burdick et al., "Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis, " American Journal of Respiratory Cell and Molecular Biology, vol. 27, no. 4, pp. 419-427, 2002.
96. C. Fertin, J. F. Nicolas, P. Gillery, B. Kalis, J. Banchereau, and F. X. Maquart, "Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents, " Cellular and Molecular Biology, vol. 37, no. 8, pp. 823-829, 1991.
97. S. M. Zurawsli, F. Vega Jr., B. Huyghe, and G. Zurawski, "Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction, " The EMBO Journal, vol. 12, no. 7, pp. 2663-2670, 1993.
98. S. Fichtner-Feigl, W. Strober, K. Kawakami, R. K. Puri, and A. Kitani, "IL-13 signaling through the IL-132 receptor is involved in induction of TGF-β 1 production and fibrosis, " Nature Medicine, vol. 12, no. 1, pp. 99-106, 2006.
99. R.M. Reiman, R. W. Thompson, C. G. Feng et al., "Interleukin-5 (IL-5) augments the progression of liver fibrosis by regulating IL-13 activity, " Infection and Immunity, vol. 74, no. 3, pp. 1471-1479, 2006.
100. J. Pesce, M. Kaviratne, T. R. Ramalingam et al., "The IL-21 receptor augmentsTh2 effector function and alternative macrophage activation, " The Journal of Clinical Investigation, vol. 116, no. 7, pp. 2044-2055, 2006.
101. M. S. Wilson, S.K. Madala, T. R. Ramalingamet al., "Bleomycin and IL-1β -mediated pulmonary fibrosis is IL-17A dependent, " The Journal of Experimental Medicine, vol. 207, no. 3, pp. 535-552, 2010.
102. A. R. Kitching and S. R. Holdsworth, "The emergence of Th17 cells as effectors of renal injury, " Journal of the American Society of Nephrology, vol. 22, no. 2, pp. 235-238, 2011.
103. S. Bamba, A. Andoh, H. Yasui, Y. Araki, T. Bamba, and Y. Fujiyama, "Matrix metalloproteinase-3 secretion from human colonic subepithelial myofibroblasts: role of interleukin-17, " Journal of Gastroenterology, vol. 38, no. 6, pp. 548-554, 2003.
104. P. Biancheri, S. L. F. Pender, F. Ammoscato et al., "The role of interleukin 17 in Crohns disease-associated intestinal fibrosis, " Fibrogenesis & Tissue Repair, vol. 6, no. 1, p. 13, 2013.
105. Y. Liu, H. Zhu, Z. Su et al., "IL-17 contributes to cardiac fibrosis following experimental autoimmune myocarditis by a PKCβ /Erk1/2/NF-B-dependent signaling pathway, " International Immunolog, vol. 24, no. 10, pp. 605-612, 2012.
106. Z. Tan, X. Qian, R. Jiang et al., "IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation, " The Journal of Immunology, vol. 191, no. 4, pp. 1835-1844, 2013.
107. T. A. Moseley, D. R. Haudenschild, L. Rose, and A. H. Reddi, "Interleukin-17 family and IL-17 receptors, " Cytokine & Growth Factor Reviews, vol. 14, no. 2, pp. 155-174, 2003.
108. Y. Okamoto, M. Hasegawa, T. Matsushita et al., "Potential roles of interleukin-17A in the development of skin fibrosis in mice, " Arthritis and Rheumatism, vol. 64, no. 11, pp. 3726-3735, 2012.
109. L. D. Hazlett, X. Jiang, and S. A. McClellan, "IL-10 function, regulation, and in bacterial keratitis, " Journal of Ocular Pharmacology andTherapeutics, vol. 30, no. 5, pp. 373-380, 2014.
110. K. W. Moore, R. De Waal Malefyt, R. L. Coffman, and A. OGarra, "Interleukin-10 and the interleukin-10 receptor, " Annual Review of Immunology, vol. 19, pp. 683-765, 2001.
111. R. P. Donnelly, H. Dickensheets, and D. S. Finbloom, "The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes, " Journal of Interferon and Cytokine Research, vol. 19, no. 6, pp. 563-573, 1999.
112. K.W. Liechty, H. B. Kim, N. S. Adzick, and T. M. Crombleholme, "Fetal wound repair results in scar formation in interleukin-10-deficient mice in a syngeneic murine model of scarless fetal wound repair, " Journal of Pediatric Surgery, vol. 35, no. 6, pp. 866-873, 2000.
113. W. H. Peranteau, L. Zhang, N. Muvarak et al., "IL-10 overexpression decreases inflammatory mediators and promotes regenerative healing in an adult model of scar formation, " Journal of Investigative Dermatology, vol. 128, no. 7, pp. 1852-1860, 2008.
114. U. Mrowietz and O. Seifert, "Keloid scarring: new treatments ahead, " Actas Dermo-Sifiliográficas, vol. 100, supplement 2, pp. 75-83, 2009.
115. S. Rutz, X. Wang, and W. Ouyang, "The IL-20 subfamily of cytokines-from host defence to tissue homeostasis, " Nature Reviews Immunology, vol. 14, no. 12, pp. 783-795, 2014.
116. N.M. Weathington, C. A. Snavely, B. B. Chen, J. Zhao, Y. Zhao, and R. K. Mallampalli, "Glycogen synthase kinase-3β stabilizes the interleukin (IL)-22 receptor from proteasomal degradation in murine lung epithelia, "The Journal of Biological Chemistry, vol. 289, no. 25, pp. 17610-17619, 2014.
117. C. Sommereyns, S. Paul, P. Staeheli, and T. Michiels, "IFNlambda (IFN-) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo, " PLoS Pathogens, vol. 4, no. 3, Article ID e1000017, 2008.
118. K. C. Meyer, "Diagnosis and management of interstitial lung disease, " Translational Respiratory Medicine, vol. 2, article 4, 2014.
119. A. Wallis and K. Spinks, "The diagnosis and management of interstitial lung diseases, " British Medical Journal, vol. 350, article h2072, 2015.
120. C. A. Feghali-Bostwick, C.G. Tsai, V. G. Valentine et al., "Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis, " The Journal of Immunology, vol. 179, no. 4, pp. 2592-2599, 2007.
121. V. Jha, G. Garcia-Garcia, K. Iseki et al., "Chronic kidney disease: global dimension and perspectives, " The Lancet, vol. 382, no. 9888, pp. 260-272, 2013.
122. F. Locatelli, P. Pozzoni, and L. Del Vecchio, "Renal replacement therapy in patients with diabetes and end-stage renal disease, " Journal of the American Society of Nephrology, vol. 15, supplement 1, pp. S25-S29, 2004.
123. R. S. Rasu, T. Crawford, H. J. Manley, and R. Balkrishnan, "Treatment of hypertension and diabetes mellitus in patients with chronic kidney disease: a review, " Expert Opinion on Pharmacotherapy, vol. 8, no. 15, pp. 2543-2551, 2007.
124. R. L. Chevalier, B. A. Thornhill, M. S. Forbes, and S. C. Kiley, "Mechanisms of renal injury and progression of renal disease in congenital obstructive nephropathy, " Pediatric Nephrology, vol. 25, no. 4, pp. 687-697, 2010.
125. C. B. Rodell, R. Rai, S. Faubel, J. A. Burdick, and D. E. Soranno, "Local immunotherapy via delivery of interleukin-10 and transforming growth factor β antagonist for treatment of chronic kidney disease, " Journal of Controlled Release, vol. 206, pp. 131-139, 2015.
126. I. Grgic, J. S. Duffield, and B. D. Humphreys, "The origin of interstitial myofibroblasts in chronic kidney disease, " Pediatric Nephrology, vol. 27, no. 2, pp. 183-193, 2012.
127. L. Himer, E. Sziksz, T. Tulassay, and A. Vannay, "Immunological and molecular mechanisms leading to fibrosis: origin of renal myofibroblasts, " in Renal Failure-The Facts, vol. 1, pp. 47-80, InTech, 2012.
128. F. Rieder and C. Fiocchi, "Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science, " Current Opinion in Gastroenterology, vol. 24, no. 4, pp. 462-468, 2008.
129. J. B. Pucilowska, K. L. Williams, and P. K. Lund, "Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models, " American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 279, no. 4, pp. G653-G659, 2000.
130. F. Rieder, J. Brenmoehl, S. Leeb, J. Scholmerich, and G. Rogler, "Wound healing and fibrosis in intestinal disease, " Gut, vol. 56, no. 1, pp. 130-139, 2007.
131. A. Andoh, Z. Zhang, O. Inatomi et al., "Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelialmyofibroblasts, " Gastroenterology, vol. 129, no. 3, pp. 969-984, 2005.
132. M. Gasparetto, I. Angriman, and G. Guariso, "The multidisciplinary health care team in the management of stenosis in Crohns disease, " Journal of Multidisciplinary Healthcare, vol. 8, pp. 167-179, 2015.
133. I. Correa, M. Veny, M. Esteller et al., "Defective IL-10 production in severe phenotypes of Crohns disease, " Journal of Leukocyte Biology, vol. 85, no. 5, pp. 896-903, 2009.
134. K. Wolk, E. Witte, U. Hoffmann et al., "IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohns disease, " The Journal of Immunology, vol. 178, no. 9, pp. 5973-5981, 2007.
135. S. Schmechel, A. Konrad, J. Diegelmann et al., "Linking genetic susceptibility to Crohns disease with Th17 cell function: IL-22 serum levels are increased in Crohns disease and correlate with disease activity andIL23Rgenotype status, " Inflammatory Bowel Diseases, vol. 14, no. 2, pp. 204-212, 2008.
136. R. H. Duerr, K. D. Taylor, S. R. Brant et al., "A genome-wide association study identifies IL23R as an inflammatory bowel disease gene, " Science, vol. 314, no. 5804, pp. 1461-1463, 2006.
137. C. Schmidt, T. Giese, B. Ludwig et al., "Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohns disease but not in ulcerative colitis, " Inflammatory Bowel Diseases, vol. 11, no. 1, pp. 16-23, 2005.
138. C. O. Elson, Y. Cong, C. T. Weaver et al., "Monoclonal antiinterleukin 23 reverses active colitis in a T cell-mediated model in mice, " Gastroenterology, vol. 132, no. 7, pp. 2359-2359, 2007.
139. J. Dambacher, F. Beigel, K. Zitzmann et al., "Therole of the novel Th17 cytokine IL-26 in intestinal inflammation, " Gut, vol. 58, no. 9, pp. 1207-1217, 2009.
140. H. Sisakian, "Cardiomyopathies: evolution of pathogenesis concepts and potential for new therapies, " World Journal of Cardiology, vol. 6, no. 6, pp. 478-494, 2014.
141. E. M. Zimmermann, R. B. Sartor, R. D. McCall, M. Pardo, D. Bender, and P. K. Lund, "Insulinlike growth factor I and interleukin 1 β messenger RNA in a rat model of granulomatous enterocolitis and hepatitis, " Gastroenterology, vol. 105, no. 2, pp. 399-409, 1993.
142. P. Krishnamurthy, M. Thal, S. Verma et al., "Interleukin-10 deficiency impairs bone marrow-derived endothelial progenitor cell survival and function in ischemicmyocardium, " Circulation Research, vol. 109, no. 11, pp. 1280-1289, 2011.
143. T. Poynard, P. Lebray, P. Ingiliz et al., "Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest), " BMC Gastroenterology, vol. 10, article 40, 2010.
144. R. Bataller and D. A. Brenner, "Liver fibrosis, " Journal of Clinical Investigation, vol. 115, no. 2, pp. 209-218, 2005.
145. V. Nobili, N. Alkhouri, A. Alisi et al., "Nonalcoholic fatty liver disease: a challenge for pediatricians, " JAMA Pediatrics, vol. 169, no. 2, pp. 170-176, 2015.
146. A. M. Miller, N. Horiguchi, W. I. Jeong, S. Radaeva, and B. Gao, "Molecular mechanisms of alcoholic liver disease: innate immunity and cytokines, " Alcoholism: Clinical and Experimental Research, vol. 35, no. 5, pp. 787-793, 2011.
147. T. E. King Jr., W. Z. Bradford, S. Castro-Bernardini et al., "A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis, "The New England Journal ofMedicine, vol. 370, no. 22, pp. 2083-2092, 2014.
148. Q. Li, "Transforming growth factor beta signaling in uterine development and function, " Journal of Animal Science and Biotechnology, vol. 5, no. 1, p. 52, 2014.
149. M. A. Travis and D. Sheppard, "TGF-β activation and function in immunity, " Annual Review of Immunology, vol. 32, pp. 51-82, 2014.
150. P. Papageorgis, "TGFβ signaling in tumor initiation, epithelialto-mesenchymal transition, and metastasis, " Journal of Oncology, vol. 2015, Article ID 587193, 15 pages, 2015.
151. R. N. Fedorak, A. Gangl, C. O. Elson et al., "Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohns disease, " Gastroenterology, vol. 119, no. 6, pp. 1473-1482, 2000.
152. H. Tilg, C. VanMontfrans, A. van den Ende et al., "Treatment of Crohns disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon , " Gut, vol. 50, no. 2, pp. 191-195, 2002.
153. S. Schreiber, R. N. Fedorak, O. H. Nielsen et al., "Safety and efficacy of recombinant human interleukin 10 in chronic active Crohns disease, " Gastroenterology, vol. 119, no. 6, pp. 1461-1472, 2000.
154. L. Steidler, W. Hans, L. Schotte et al., "Treatment of murine colitis by Lactococcus lactis secreting interleukin-10, " Science, vol. 289, no. 5483, pp. 1352-1355, 2000.
155. H. Braat, P. Rottiers, D. W. Hommes et al., "A phase I trial with transgenic bacteria expressing interleukin-10 in Crohns disease, " Clinical Gastroenterology and Hepatology, vol. 4, no. 6, pp. 754-759, 2006.
156. G. Barbara, Z. Xing, C. M. Hogaboam, J. Gauldie, and S. M. Collins, "Interleukin 10 gene transfer prevents experimental colitis in rats, " Gut, vol. 46, no. 3, pp. 344-349, 2000.
157. J. O. Lindsay, C. J. Ciesielski, T. Scheinin, F. M. Brennan, and H. J. Hodgson, "Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic formurine colitis, " Gut, vol. 52, no. 3, pp. 363-369, 2003.
158. C. Hofstetter, M. Flondor, S. Hoegl, H. Muhl, and B. Zwissler, "Interleukin-10 aerosol reduces proinflammatory mediators in bronchoalveolar fluid of endotoxemic rat, " Critical Care Medicine, vol. 33, no. 10, pp. 2317-2322, 2005.
159. P. Lichte, R. Pfeifer, P. Kobbe et al., "Inhalative IL-10 treatment after bilateral femoral fractures affect pulmonary inflammation in mice, " Annals of Anatomy, vol. 200, pp. 73-78, 2015.
160. K. M. Wissing, E. Morelon, C. Legendre et al., "A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy, " Transplantation, vol. 64, no. 7, pp. 999-1006, 1997.
161. H. Rachmawati, L. Beljaars, C. Reker-Smit et al., "Intravenous administration of recombinant human IL-10 suppresses the development of Anti-Thy 1-induced glomerulosclerosis in rats, " PDA Journal of Pharmaceutical Science and Technology, vol. 65, no. 2, pp. 116-130, 2011.
162. D. R. Nelson, G.Y. Lauwers, J.Y.N. Lau, and G. L. Davis, "Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders, " Gastroenterology, vol. 118, no. 4, pp. 655-660, 2000.
163. D. R. Nelson, Z. Tu, C. Soldevila-Pico et al., "Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect, " Hepatology, vol. 38, no. 4, pp. 859-868, 2003.